Almac Group announced the completion of a £20 million investment in its cold chain management capabilities with the opening of a 95,000sq ft. custom built cold store facility at its global headquarters in Northern Ireland.
The cold store has been built in response to customer requirements which includes consideration to the rapidly growing area of orphan drug products, changes to regulatory compliance and a more stringent focus on data across the supply chain. The additional capacity and tailored design also offers clients the opportunity to scale up with Almac as their biologic/biosimilar product portfolio increases.
The new facility complements Almac’s existing global clinical supply and drug product capabilities by boasting over 3,000 pallet spaces including -15°C to -25°C storage capacity, additional 2°C – 8°C secondary production rooms, 3PL processing areas and a custom designed clinical labelling suite. Supplementary office space has also been included to accommodate an additional 100 new employees who will be recruited as a result of the expansion.
“Once again, Almac has set the industry standard with another significant investment in our comprehensive global clinical and commercial supply chain offering,” Alan Armstrong, CEO Almac Group said. “This new facility at our global headquarters expands our cold storage capacity by 300% and our frozen storage capabilities by over 50%, enabling us to better serve our clients, and ultimately patients, worldwide thereby maintaining our position as a global leader in the life sciences sector.”